» Articles » PMID: 24448240

Fragmented Sleep Accelerates Tumor Growth and Progression Through Recruitment of Tumor-associated Macrophages and TLR4 Signaling

Overview
Journal Cancer Res
Specialty Oncology
Date 2014 Jan 23
PMID 24448240
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Sleep fragmentation (SF) is a highly prevalent condition and a hallmark of sleep apnea, a condition that has been associated with increased cancer incidence and mortality. In this study, we examined the hypothesis that sleep fragmentation promotes tumor growth and progression through proinflammatory TLR4 signaling. In the design, we compared mice that were exposed to sleep fragmentation one week before engraftment of syngeneic TC1 or LL3 tumor cells and tumor analysis four weeks later. We also compared host contributions through the use of mice genetically deficient in TLR4 or its effector molecules MYD88 or TRIF. We found that sleep fragmentation enhanced tumor size and weight compared with control mice. Increased invasiveness was apparent in sleep fragmentation tumors, which penetrated the tumor capsule into surrounding tissues, including adjacent muscle. Tumor-associated macrophages (TAM) were more numerous in sleep fragmentation tumors, where they were distributed in a relatively closer proximity to the tumor capsule compared with control mice. Although tumors were generally smaller in both MYD88(-/-) and TRIF(-/-) hosts, the more aggressive features produced by sleep fragmentation persisted. In contrast, these more aggressive features produced by sleep fragmentation were abolished completely in TLR4(-/-) mice. Our findings offer mechanistic insights into how sleep perturbations can accelerate tumor growth and invasiveness through TAM recruitment and TLR4 signaling pathways.

Citing Articles

Sleep and cancer mortality in the Cancer Prevention Study-II.

Donzella S, Deubler E, Patel A, Phipps A, Zhong C Cancer Causes Control. 2024; 35(12):1541-1555.

PMID: 39240291 DOI: 10.1007/s10552-024-01910-3.


Sex-specific associations between habitual snoring and cancer prevalence: insights from a US Cohort Study.

Ding Q, Herrin J, Kryger M Sleep Adv. 2024; 5(1):zpae051.

PMID: 39156215 PMC: 11329803. DOI: 10.1093/sleepadvances/zpae051.


Epigenetics and aging: relevance for sleep medicine.

Cortese R Curr Opin Pulm Med. 2024; 30(6):607-612.

PMID: 39082896 PMC: 11611687. DOI: 10.1097/MCP.0000000000001109.


A review of obstructive sleep apnea and lung cancer: epidemiology, pathogenesis, and therapeutic options.

Yuan F, Hu Y, Xu F, Feng X Front Immunol. 2024; 15:1374236.

PMID: 38605948 PMC: 11007033. DOI: 10.3389/fimmu.2024.1374236.


Objectively measured peri-vaccination sleep does not predict COVID-19 breakthrough infection.

Jaiswal S, Gadaleta M, Quer G, Radin J, Waalen J, Ramos E Sci Rep. 2024; 14(1):4655.

PMID: 38409137 PMC: 10897487. DOI: 10.1038/s41598-024-53743-4.


References
1.
Kakizaki M, Kuriyama S, Sone T, Ohmori-Matsuda K, Hozawa A, Nakaya N . Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer. 2008; 99(9):1502-5. PMC: 2579702. DOI: 10.1038/sj.bjc.6604684. View

2.
Sigurdardottir L, Valdimarsdottir U, Fall K, Rider J, Lockley S, Schernhammer E . Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2012; 21(7):1002-11. PMC: 3392423. DOI: 10.1158/1055-9965.EPI-12-0116. View

3.
Abrams B . Cancer and sleep apnea--the hypoxia connection. Med Hypotheses. 2006; 68(1):232. DOI: 10.1016/j.mehy.2006.06.037. View

4.
Jiao L, Duan Z, Sangi-Haghpeykar H, Hale L, White D, El-Serag H . Sleep duration and incidence of colorectal cancer in postmenopausal women. Br J Cancer. 2013; 108(1):213-21. PMC: 3553538. DOI: 10.1038/bjc.2012.561. View

5.
Kaushal N, Ramesh V, Gozal D . Human apolipoprotein E4 targeted replacement in mice reveals increased susceptibility to sleep disruption and intermittent hypoxia. Am J Physiol Regul Integr Comp Physiol. 2012; 303(1):R19-29. PMC: 3404642. DOI: 10.1152/ajpregu.00025.2012. View